IceCure Medical's prelim 2025 revenue misses expectations

Overview

• Israel cryoablation firm's preliminary 2025 revenue missed analyst expectations

• Company experienced strong U.S. demand following FDA authorization for ProSense

• Record European sales driven by U.S. clearance and growing ProSense adoption

Outlook

• IceCure expects higher ProSense® sales in 2026 due to U.S. and European demand

• Company anticipates more reimbursement coverage for ProSense® procedures in 2026

• Terumo to submit breast cancer clearance request in Japan in first half of 2026

Result Drivers

• FDA AUTHORIZATION - U.S. FDA marketing authorization for ProSense® drove strong demand in North America, particularly for low-risk breast cancer treatment in women aged 70 and above

• EUROPEAN SALES - Record European sales driven by U.S. clearance and growing adoption of ProSense® cryoablation for breast cancer

• CLINICAL EVIDENCE - Record number of peer-reviewed publications and presentations demonstrate growing clinical evidence for ProSense® across various cancer types

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Icecure Medical Ltd is $3.13, about 340% above its January 9 closing price of $0.71

Press Release: ID:nPn5QLbNwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.